Is cell therapy the answer for hematological malignancies?

摘要

Recent remarkable progresses achieved in the field of human cell-based therapies have led to promising opportunities and therapeutic advances in the management of some hematological malignancies (HM) [1,2]. Indeed, the introduction in clinical practice of chimeric antigen receptor T cells (CAR-T) to treat B-cell malignancies, or alternative cell-based approaches to modulate the immunologic response against HM, have allowed outstanding success of translational research [3,4],potentially opening a new era in oncology [2,5]. An interesting review recently published in this journal summarized the evolution of cell therapy, including the promising role of these new cell-based treatments, as well as some concerns related to their use in clinical practice [1]. Based on their long experience, the authors provided a clinical point of view of the current position of these cell-based therapies in the treatment algorithm, influenced by the continuous introduction of innovative treatments, such as checkpoint inhibitors, aibodydrug conjugates, and bi-specific T-cell engagers [68].